Roivant Sciences Ltd (NASDAQ:ROIV) is set to release its Q4 2025 earnings on May 29, 2025. The consensus estimate for Q4 2025 ...

Q4 2024 Earnings Call Transcript May 29, 2025 Roivant Sciences Ltd. misses on earnings expectations. Reported EPS is $-0.22 ...

We recently published a list of While Wall Street Naps, These 10 Stocks Run Wild. In this article, we are going to take a ...

Roivant Sciences (NASDAQ:ROIV) will release its quarterly earnings report on Thursday, 2025-05-29. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Roivant ...

Monday, Roivant Sciences announced an asset sale to Roche. The biotech is slated to earn $5.2 billion upon closing, plus a $110 milestone payment once a late-stage trial commences. Nonetheless ...

Roivant Sciences (NASDAQ:ROIV) shares are trading down by -40% across the past 12 months, and down 24% since the company joined the Nasdaq via a merger with the Special Purpose Acquisition Company ...

Roivant Sciences exhibits a strong financial outlook, backed by its substantial cash position, strategic acquisitions, and efficient R&D expense management. The company's innovative drug pipeline ...

Roivant Sciences' shares are up more than 42% over the past year. The company recently released a report on a phase 3 trial of its atopic dermatitis treatment. The company's other main therapy ...

Roivant Sciences BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that its founder Vivek Ramaswamy has ...

Roivant Sciences (NASDAQ:ROIV) has observed the following analyst ratings within the last quarter: These 7 analysts have an average price target of $16.57 versus the current price of Roivant ...

Analysts anticipate Roivant Sciences to report an earnings per share (EPS) of $-0.16. The announcement from Roivant Sciences is eagerly anticipated, with investors seeking news of surpassing estimates ...